Cargando…

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective

BACKGROUND: Treatment cycling with biologic disease-modifying anti-rheumatic drugs, such as tumor necrosis factor inhibitors (TNFi), is common among patients with rheumatoid arthritis (RA) and can result in reduced clinical efficacy and increased economic burden. Tofacitinib is an oral Janus kinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claxton, Lindsay, Taylor, Matthew, Soonasra, Arif, Bourret, Jeffrey A., Gerber, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397979/ https://www.ncbi.nlm.nih.gov/pubmed/29897007 http://dx.doi.org/10.18553/jmcp.2018.17220

Ejemplares similares

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States
por: Claxton, Lindsay, et al.
Publicado: (2016)

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
por: Bergman, Martin, et al.
Publicado: (2021)

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
por: Fleischmann, R, et al.
Publicado: (2016)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
por: Strand, Vibeke, et al.
Publicado: (2018)

Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
por: Fleischmann, Roy, et al.
Publicado: (2022)

Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis
por: Stavrakas, Spyros, et al.
Publicado: (2011)

Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis
por: Gao, Yan, et al.
Publicado: (2023)

Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective
por: Lin, J., et al.
Publicado: (2014)

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014)

The role of nurse practitioners in delivering rheumatology care and services: Results of a U.S. survey
por: Riley, Lydia, et al.
Publicado: (2017)

Values-Based Foundation for a U.S. Single Payer Health System Model
por: Markowitz, Walter, et al.
Publicado: (2021)

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
por: Dénarié, Delphine, et al.
Publicado: (2017)

Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs
por: Chambers, James D., et al.
Publicado: (2016)

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis
por: Mori, Shunsuke, et al.
Publicado: (2021)

The occurrence of varicella after zoster vaccination in a patient with rheumatoid arthritis receiving tofacitinib
por: KAO, Chung-Mao, et al.
Publicado: (2021)

Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
por: Inanc, Nevsun, et al.
Publicado: (2023)

Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
por: Kim, Joon Wan, et al.
Publicado: (2013)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
por: Hansen, Karen E., et al.
Publicado: (2022)

Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada
por: Movahedi, Mohammad, et al.
Publicado: (2023)

Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months
por: Bykerk, Vivian P., et al.
Publicado: (2021)

Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis
por: Tanaka, Keisuke, et al.
Publicado: (2023)

Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
por: Grigoropoulos, Ioannis, et al.
Publicado: (2019)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
por: Li, Zhan-Guo, et al.
Publicado: (2018)

Precautions before starting tofacitinib in persons with rheumatoid arthritis
por: Swarnakar, Raktim, et al.
Publicado: (2022)

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
por: Mortezavi, Mahta, et al.
Publicado: (2023)

Posttraumatic Stress Disorder, Depression, Anxiety, and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis
por: Desilet, Luke W., et al.
Publicado: (2020)

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
por: Kaine, Jeffrey, et al.
Publicado: (2020)

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016)

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
por: Salem, Heba F., et al.
Publicado: (2022)

Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study
por: Calabrese, Leonard H., et al.
Publicado: (2020)

Methotrexate/tofacitinib/tozinameran interaction: COVID-19 pneumonia: case report
Publicado: (2022)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program
por: Sands, Bruce E, et al.
Publicado: (2021)

Tofacitinib Citrate for Ulcerative Keratitis in a Patient with Rheumatoid Arthritis
por: Meadow, Philip B., et al.
Publicado: (2014)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_821r9c18hdtn4tul9fslanl818